Pharmacy Practice & Science Department Highlights: September 2024
Publications
Ivo Abraham
Abraham I, Calamia M, Alkhatib NS, Pondel M, MacDonald K. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of Medical Economics 2024;27(Suppl.3):9-23. ////////// MacDonald K, Pondel M, Abraham I. Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell cancer. Journal of Medical Economics 2024;27(Suppl.3):24-33. //////////Obeng-Kusi M, Martin JR, Roe D, Erstad B, Abraham I. Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves. Expert Review of Pharmacoeconomics and Outcomes Research 2024;24:923-932.
Abraham I, Calamia M, Pondel M, MacDonald K. Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic non-squamous non-small cell lung cancer. Journal of Medical Economics 2024;27(Suppl.3):36-50.
Obeng-Kusi M, Martin JR, Roe D, Erstad B, Abraham I. Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves. Expert Review of Pharmacoeconomics and Outcomes Research 2024;24:923-932.
MacDonald K, Pondel M, Abraham I. Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell cancer. Journal of Medical Economics 2024;27(Suppl.3):24-33.
Abraham I, Calamia M, Alkhatib NS, Pondel M, MacDonald K. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma. Journal of Medical Economics 2024;27(Suppl.3):9-23.
Bonnie LaFleur
Narendran N, Volpe S, Ramadan I, Herbert JR, LaFleur B, Samargandy S, Le CH, Chang EH. A prospective longitudinal study assessing the impact of rhinovirus and bacterial infections in acute exacerbations of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2024 Sep 3. doi: 10.1002/alr.23431. Epub ahead of print. PMID: 39225695.
Grants
Bonnie LaFleur
University of Arizona Skin Institute Seed Grant: "Deconvolution Methods to Guide Opportunities and Timing to Intervene with Topical Immunoprevention Strategies in cSCC"
UArizona's Research, Innovation & Impact, Accelerate for Success Seed Grant (Co-PI with Clara Curiel in the AZCC) "Deconvolution methods to guide opportunities and timing to intervene with topical immunoprevention strategies"
Presentations
“The All of Us Research Program.” 2024 Pharmacogenomics Global Research Network (PGRN) Annual Meeting, Columbus, OH.
“Opportunities for Discovery in Precision Medicine: Big Data and Diversity.” Northwestern University Feinberg School of Medicine Department of Pharmacology Seminar Series, Chicago, IL